Phenotypic spectrum associated with a CRADD founder variant underlying frontotemporal predominant pachygyria in the Finnish population.


Journal

European journal of human genetics : EJHG
ISSN: 1476-5438
Titre abrégé: Eur J Hum Genet
Pays: England
ID NLM: 9302235

Informations de publication

Date de publication:
08 2019
Historique:
received: 28 09 2018
accepted: 07 03 2019
revised: 13 02 2019
pubmed: 28 3 2019
medline: 17 6 2020
entrez: 28 3 2019
Statut: ppublish

Résumé

Intellectual disability (ID), megalencephaly, frontal predominant pachygyria, and seizures, previously called "thin" lissencephaly, are reported to be caused by recessive variants in CRADD. Among five families of different ethnicities identified, one homozygous missense variant, c.509G>A p.(Arg170His), was of Finnish ancestry. Here we report on the phenotypic variability associated for this potential CRADD founder variant in 22 Finnish individuals. Exome sequencing was used to identify candidate genes in Finnish patients presenting with ID. Targeted Sanger sequencing and restriction enzyme analysis were applied to screen for the c.509G>A CRADD variant in cohorts from Finland. Detailed phenotyping and genealogical studies were performed. Twenty two patients were identified with the c.509G>A p.(Arg170His) homozygous variant in CRADD. The majority of the ancestors originated from Northeastern Finland indicating a founder effect. The hallmark of the disease is frontotemporal predominant pachygyria with mild cortical thickening. All patients show ID of variable severity. Aggressive behavior was found in nearly half of the patients, EEG abnormalities in five patients and megalencephaly in three patients. This study provides detailed data about the phenotypic spectrum of patients with lissencephaly due to a CRADD variant that affects function. High inter- and intrafamilial phenotypic heterogeneity was identified in patients with pachygyria caused by the homozygous CRADD founder variant. The phenotype variability suggests that additional genetic and/or environmental factors play a role in the clinical presentation. Since frontotemporal pachygyria is the hallmark of the disease, brain imaging studies are essential to support the molecular diagnosis for individuals with ID and a CRADD variant.

Identifiants

pubmed: 30914828
doi: 10.1038/s41431-019-0383-8
pii: 10.1038/s41431-019-0383-8
pmc: PMC6777631
doi:

Substances chimiques

CRADD Signaling Adaptor Protein 0
CRADD protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1235-1243

Commentaires et corrections

Type : ErratumIn

Références

Eur J Med Genet. 2012 Dec;55(12):753-7
pubmed: 23022981
Annu Rev Genet. 2011;45:81-104
pubmed: 21910631
Semin Cell Dev Biol. 2018 Apr;76:33-75
pubmed: 28951247
Exp Brain Res. 2006 Aug;173(2):322-33
pubmed: 16724181
Arch Neurol. 1979 Feb;36(2):88-94
pubmed: 420628
Nat Rev Genet. 2000 Dec;1(3):182-90
pubmed: 11252747
Neurology. 1983 Jan;33(1):57-66
pubmed: 6681560
Ann Med. 2011 May;43(3):235-48
pubmed: 20854213
Am J Med Genet A. 2017 Sep;173(9):2539-2544
pubmed: 28686357
Mech Ageing Dev. 2007 Feb;128(2):213-21
pubmed: 17188333
Biochem J. 2012 Jun 15;444(3):591-9
pubmed: 22515271
Nature. 1997 Jan 2;385(6611):86-9
pubmed: 8985253
Cell Death Differ. 2012 Aug;19(8):1370-80
pubmed: 22343713
Hum Genet. 2003 May;112(5-6):441-56
pubmed: 12627295
Clin Genet. 2014 Feb;85(2):101-10
pubmed: 23895455
Mol Psychiatry. 2017 Nov;22(11):1604-1614
pubmed: 27457812
Nat Genet. 2000 Sep;26(1):122-7
pubmed: 10973264
Genome Res. 1996 Sep;6(9):870-5
pubmed: 8889554
Am J Hum Genet. 2018 May 3;102(5):760-775
pubmed: 29706349
Nature. 1993 Aug 19;364(6439):717-21
pubmed: 8355785
PLoS One. 2012;7(1):e28936
pubmed: 22279524
Brain. 2012 May;135(Pt 5):1348-69
pubmed: 22427329
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
Am J Med Genet C Semin Med Genet. 2014 Jun;166C(2):198-210
pubmed: 24862549
Duodecim. 1985;101(5):465-76
pubmed: 3987562
Annu Rev Genomics Hum Genet. 2010;11:161-87
pubmed: 20822471
Nat Commun. 2019 Jan 24;10(1):410
pubmed: 30679432
Am J Hum Genet. 2016 Nov 3;99(5):1117-1129
pubmed: 27773430
Mol Syndromol. 2016 Sep;7(4):220-233
pubmed: 27781032
Am J Med Genet A. 2017 Jun;173(6):1473-1488
pubmed: 28440899
Ann Med. 2012 Jun;44(4):369-74
pubmed: 21495784
Lancet Neurol. 2014 Jul;13(7):710-26
pubmed: 24932993
Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14314-20
pubmed: 16183742
Nat Genet. 1999 Oct;23(2):233-6
pubmed: 10508524
Hum Mutat. 2013 Nov;34(11):1458-66
pubmed: 23904198
J Clin Invest. 1992 Jul;90(1):160-4
pubmed: 1634607

Auteurs

Daniel L Polla (DL)

Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.
CAPES Foundation, Ministry of Education of Brazil, Brasília, Brazil.

Elisa Rahikkala (E)

Department of Clinical Genetics, PEDEGO Research Unit and Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.

Michaela K Bode (MK)

Department of Diagnostic Radiology, Oulu University Hospital and Medical Research Center Oulu, Oulu, Finland.

Tuomo Määttä (T)

Disability Services, Joint Authority for Kainuu, Kainuu, Finland.

Teppo Varilo (T)

Department of Medical Genetics, University of Helsinki, Helsinki, Finland.

Thyrza Loman (T)

Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.

Anju K Philips (AK)

Department of Medical Genetics, University of Helsinki, Helsinki, Finland.

Mitja Kurki (M)

Psychiatric & Neurodevelopmental Genetics Unit, Massachusetts General Hospital, Boston, MA, USA.
The Stanley Center for Psychiatric Research, The Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.

Aarno Palotie (A)

Psychiatric & Neurodevelopmental Genetics Unit, Massachusetts General Hospital, Boston, MA, USA.
The Stanley Center for Psychiatric Research, The Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.

Jarmo Körkkö (J)

Northern Ostrobothnia Hospital District, Center for Intellectual Disability Care, 90220, Oulu, Finland.

Päivi Vieira (P)

Clinic for Children and Adolescents, PEDEGO Research Unit and Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.

Kristiina Avela (K)

Department of Clinical Genetics, Helsinki University Hospital, Helsinki, Finland.

Valérie Jacquemin (V)

Medical Genetics, IRIBHM, Université Libre de Bruxelles, Brussels, Belgium.

Isabelle Pirson (I)

Medical Genetics, IRIBHM, Université Libre de Bruxelles, Brussels, Belgium.

Marc Abramowicz (M)

Medical Genetics, IRIBHM, Université Libre de Bruxelles, Brussels, Belgium.

Arjan P M de Brouwer (APM)

Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.

Outi Kuismin (O)

Department of Clinical Genetics, PEDEGO Research Unit and Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.
Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.

Hans van Bokhoven (H)

Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.

Irma Järvelä (I)

Department of Medical Genetics, University of Helsinki, Helsinki, Finland. irma.jarvela@helsinki.fi.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH